GLP-1s and Inflammation: What the Research Is Showing

For years, GLP-1 medications were known mainly for blood sugar control and weight management. Today, a fast-growing body of research is asking a different question: do these medications also influence inflammation and immune system activity — and if so, what might that mean for people living with inflammatory and autoimmune conditions?

It's an important question, and an actively evolving one. Here's what the science actually shows so far.

GLP and Inflammation: What researchers are finding

GLP-1 receptors aren't limited to the pancreas — they're also present on several types of immune cells. That single fact is what opened the door to this entire area of research. Scientists have observed that GLP-1 medications appear to influence inflammatory signaling pathways, oxidative stress, and immune cell behavior in ways that go beyond their effects on blood sugar and weight.

A few specific findings from recent research:

• A meta-analysis of 13 randomized controlled trials found that GLP-1 receptor agonists reduced C-reactive protein, a key marker of systemic inflammation, by 44 to 55 percent.

• Laboratory research has linked GLP-1 activity to suppression of NF-kB and the NLRP3 inflammasome, two pathways heavily implicated in autoimmune and inflammatory disease.

• A 2026 cardiovascular outcomes study presented at the American Diabetes Association's Scientific Sessions found that, among adults with both obesity and an autoimmune disease, those on GLP-1 medications had fewer emergency department visits, fewer serious cardiac events, and lower mortality than those who weren't.

• Researchers at the University of Colorado Cancer Center have observed improvements in immune function and reduced inflammation in GLP-1 users with obesity — findings with implications for both cancer immunology and autoimmune disease, and active areas of continued study.

• Early case reports and scoping reviews are exploring GLP-1s as a possible adjunct therapy in conditions such as rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and Sjögren's syndrome.

  
  

Conditions currently being studied in this context include rheumatoid arthritis, psoriatic arthritis, psoriasis, inflammatory bowel disease (Crohn's and ulcerative colitis), lupus, and multiple sclerosis, among others.

The full picture — including the open questions

Good science reporting means showing the whole picture, not just the encouraging parts. A few things are worth knowing:

Much of the benefit may be indirect. Obesity itself is a pro-inflammatory state — excess visceral fat releases cytokines like TNF-alpha and IL-6, and weight loss on its own tends to lower inflammation. Researchers in this field are still working to separate how much of GLP-1s' anti-inflammatory effect comes from weight loss itself versus a direct action on immune cells. As one researcher in the space put it, this distinction matters a great deal for understanding how these drugs actually work.

The findings aren't uniformly positive. A 2025 real-world study of more than 290,000 matched patients found GLP-1 users had a higher incidence of certain autoimmune conditions — including autoimmune thyroiditis, ankylosing spondylitis, and psoriasis — compared to non-users. This doesn't cancel out the anti-inflammatory findings, but it's a reminder that the relationship between GLP-1s and the immune system is complex and not fully understood.

Experts are urging caution about overclaiming. As one rheumatology researcher recently noted, the immune system is highly complex, and it's premature to say GLP-1 medications treat autoimmune disease directly. The best current evidence is described as largely indirect, and more controlled research is needed to know how much of the benefit is specific to GLP-1s versus a byproduct of metabolic improvement.

What we're seeing in our own practice

In our own practice, we've had patients on a GLP journey mention feeling generally better as inflammation-related symptoms ease — less stiffness, more energy, improved mobility — alongside their other changes. We can't say how much of that comes from the metabolic shifts the research above already explains versus a more direct anti-inflammatory effect; that distinction is part of what makes this such an interesting area to watch. These are individual observations, not clinical outcomes data, and they should be read in that light.

Why this matters

GLP-1 medications are not approved to treat autoimmune or inflammatory disease, and they shouldn't be viewed as a substitute for established autoimmune treatment. What they represent is a genuinely interesting and still-unfolding area of medical research — one more example of how connected metabolic health, inflammation, and immune function turn out to be.

At Elite Integrative MediSun, we follow the research as it develops and believe our patients deserve an honest, current picture of the science — including its uncertainties. If you're curious whether a GLP-1 program could be a fit for your broader health goals, we're happy to talk through it.

☀️ Book your consultation with Elite Integrative MediSun to discuss your personalized health goals.

This article is for informational purposes only and is not medical advice. GLP-1 medications are not FDA-approved for the treatment of autoimmune or inflammatory disease. Talk with a qualified provider about whether a GLP-1 program is appropriate for you.